Change in the Board of Managing Directors at Boehringer Ingelheim
Ingelheim, Germany – 26 August 2019 – The research-driven pharmaceutical company Boehringer Ingelheim today announced changes in its Board of Managing Directors.
Allan Hillgrove, Member of the Board of Managing Directors responsible for the Human Pharma and the Biopharma business, will step down from the Board and retire at the end of this year after 37 committed and successful years within the corporation. After 19 years in Germany, he and his wife will return to Australia, their home country, where their children live.
Allan Hillgrove joined Boehringer Ingelheim in 1982 in Australia as a sales representative in Animal Health. Throughout his career, he held numerous Human Pharma management positions in Australia and Corporate, including Head of Corporate Department Respiratory Marketing. In 2013, the shareholders appointed him to the Board of Managing Directors and entrusted him with the leadership of the Human Pharma Business, adding responsibility for the Biopharma Business in 2018.
Christian Boehringer, Chairman of the Shareholders’ Committee says: ‘Innovative medicines like SPIRIVA® and OFEV® for respiratory as well as JARDIANCE® and TRAJENTA® in diabetes have substantially improved therapy options for patients. Allan Hillgrove has made a very significant contribution to this and thus to the sustainable development of the company. The shareholders would like to express their highest appreciation for his many years of dedicated service for Boehringer Ingelheim, and wish him and his family all the best for the years to come.’
The shareholders have decided to appoint Dr Carine Brouillon to the Board of Managing Directors, effective January 1st, 2020 as his successor. Since she joined Boehringer Ingelheim in 2018, Carine Brouillon has been leading the Therapeutic Areas for prescription medicines. She has an academic background in natural science and economics as well as broad international expertise in product, marketing, and commercial strategies. Carine Brouillon will continue to align the human pharmaceutical business to future needs of patients.
Also at the end of this year, Dr Joachim Hasenmaier will retire and step down as member of the Board of Managing Directors and from his responsibility for the Animal Health business. Joachim Hasenmaier joined Boehringer Ingelheim in 2001 as Head of the Animal Health Division. He led the business into a period of successful growth, which included acquisitions such as parts of Fort Dodge, an animal health company, in 2009. In 2012, he was appointed as Member of the Board of Managing Directors with responsibility for the two businesses, Animal Health as well as Consumer Health Care.
‘In addition to many years of fruitful business development in the animal health business, Joachim Hasenmaier has made a significant contribution to the planning and implementation of the successful business swap in which Boehringer Ingelheim took over the animal health business of Sanofi (Merial). Together with his team, he then integrated the Merial organization into our Animal Health Business Unit. The shareholders would like to express their highest appreciation for his many years of dedication to Boehringer Ingelheim, and wish him and his family all the best for the years to come’, notes Christian Boehringer, Chairman of the Shareholders’ Committee.
The shareholders have decided to appoint Jean Scheftsik de Szolnok as Member of the Board of Managing Directors and new Head of the Animal Health Business Unit, effective January 1st, 2020. Jean Scheftsik de Szolnok joined the corporation in 1987. Since September 2017, he has been the Country Managing Director of France. In this role, he was instrumental in managing the Merial integration and further development of the Lyon site as a research, development and production site for the animal health business. Before that, he held various leadership positions in Germany as well as in Canada, Belgium and France.
For Boehringer Ingelheim as an innovation-driven company, continuous success of all aspects of organizational and employee development as well as its attractiveness as an employer is essential. These topics have in the meantime become a substantially increasing part of the Chairman’s role. In order to reflect this trend, the responsibility for the overall people strategy will move under the leadership of the Chairman of the Board of Managing Directors, effective October 1st, 2019. At the same time, new technologies and digital transformation have moved many tasks of enabling Corporate functions closer together. Hence, some Human Resources activities will become part of the responsibility of the Board Division Finance.
As a result, Dr Andreas Neumann has decided to step down from the Board of Managing Directors at the end of September and will leave the corporation after more than eight years of dedicated work for the corporation. He held the position of General Counsel from 2011 until 2015. During this time, the global compliance concept and a corresponding organization was established. Andreas Neumann then was appointed to the Board of Managing Directors with responsibility for Human Resources.
Christian Boehringer, Chairman of the Shareholders‘ Committee, said: ‘During the tenure of Andreas Neumann, the global framework of OUR FOCUS was created, a central building block for the development and transformation of our organization. At the same time, Diversity & Inclusion as well as people development have been important topics of his leadership. The Shareholders would like to express their highest appreciation for his many years of dedication to Boehringer Ingelheim, and wish him and his family all the best for the years to come.’
Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost
3.2 billion euros, corresponded to 18.1 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.